Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M605Revenue $M232Net Margin (%)7.0Z-Score14.4
Enterprise Value $M518EPS $1.2Operating Margin %16.1F-Score5
P/E(ttm))65.9Cash Flow Per Share $4.4Pre-tax Margin (%)9.8Higher ROA y-yN
Price/Book2.210-y EBITDA Growth Rate %0Quick Ratio6.4Cash flow > EarningsN
Price/Sales2.75-y EBITDA Growth Rate %12.8Current Ratio8.1Lower Leverage y-yY
Price/Cash Flow8.2y-y EBITDA Growth Rate %-57.5ROA % (ttm)5.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)6.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M13.6ROI % (ttm)6.6Gross Margin Increase y-yY

Gurus Latest Trades with HITK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HITKMario Gabelli 2014-03-31 Add0.01%$43.17 - $43.515
($43.34)
$ 43.490%Add 25.72%276,167
HITKMario Gabelli 2013-09-30 Buy 0.06%$33.02 - $43.19
($38.28)
$ 43.4914%New holding, 218667 sh.218,667
HITKJoel Greenblatt 2012-09-30 Sold Out -0.12%$29.2 - $36.54
($33.04)
$ 43.4932%Sold Out0
HITKJoel Greenblatt 2011-09-30 Add0.06%$24.61 - $34.71
($29.67)
$ 43.4947%Add 39.49%38,446
HITKJoel Greenblatt 2011-06-30 Buy 0.11%$20.45 - $28.74
($25.94)
$ 43.4968%New holding, 27561 sh.27,561
HITKArnold Van Den Berg 2009-09-30 Buy 0.03%$9.25 - $22.43
($15.34)
$ 43.49184%New holding, 19215 sh.19,215
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HITK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HITK Mario Gabelli 2014-03-31276,1672.030.07+25.72%
Premium Most recent portfolio changes are included for Premium Members only!


HITK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
April Gary MPresident, HCP Division 2013-12-13Sell6,873$43.061view
SELTZER REUBENVice Chairman, Business Dev't 2013-10-10Sell11,250$43.130.83view
SELTZER DAVID SCEO, President, Sec'y, Treas., 10% Owner 2013-10-08Sell23,000$43.090.93view
GOLDWYN MARTIN MDirector 2013-10-04Sell1,500$43.10.9view
PETERS WILLIAM JEVP & CFO 2013-10-03Sell21,250$43.110.88view
SELTZER REUBENVice Chairman, Business Dev't 2013-10-02Sell11,250$43.130.83view
Simpson Bruce WDirector 2013-10-02Sell25,468$43.150.79view
April Gary MPresident, HCP Division 2013-09-30Sell3,125$43.080.95view
GOLDWYN MARTIN MDirector 2013-09-27Sell3,000$43.10.9view
PETERS WILLIAM JVP and CFO 2013-02-05Sell4,639$3814.45view

Press Releases about HITK :

    Quarterly/Annual Reports about HITK:

    News about HITK:

    Articles On GuruFocus.com
    Six Royce Reductions in Third Quarter Oct 09 2013 
    Chuck Royce Reductions – Lessons on Hold’em or Fold’em Sep 10 2013 
    Good ROE, ROA Jan 21 2013 
    The Royce Funds Makes Moves on Some Tech Stocks Dec 07 2012 
    comment on HITK Jul 13 2012 
    comment on HITK Jul 13 2012 
    There’s No Magic Bullet Feb 14 2012 
    Value Idea Contest, A Year Later Jan 20 2012 
    HITK: A Promising Generic Drug Value Play Jul 19 2011 
    March Value Idea Contest Results Announcement; April Contest Is Now Accepting Submissions Apr 12 2012 

    More From Other Websites
    Akorn plans $440M acquisition of VersaPharm May 09 2014
    HI TECH PHARMACAL CO INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Apr 17 2014
    Akorn Completes Acquisition of Hi-Tech Pharmacal Apr 17 2014
    Repligen Corporation Set to Join the S&P SmallCap 600 Apr 15 2014
    Akorn gets FTC clearance for Hi-Tech Pharmacal deal Apr 14 2014
    Akorn Receives FTC Clearance for Hi-Tech Pharmacal Acquisition Apr 14 2014
    HI TECH PHARMACAL CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Mar 21 2014
    HI TECH PHARMACAL CO INC Financials Mar 15 2014
    HI TECH PHARMACAL CO INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 12 2014
    HI TECH PHARMACAL CO INC Files SEC form 10-Q, Quarterly Report Mar 11 2014
    Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014 Mar 11 2014
    Akorn Guidance Worries Street As Strategy Hits Delays Mar 03 2014
    Akorn Q4 Meets But Guidance Disappoints, Stock Down Mar 03 2014
    IntelGenx Technologies: A Small Cap Company With The Potential For Significant Gains Jan 26 2014
    Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day) Jan 23 2014
    Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day) Jan 23 2014
    Allergan Wins Order Blocking Copies of Lumigan Until 2027 Jan 14 2014
    Hi-Tech Pharmacal in $25M Medicaid settlement Dec 26 2013
    HI TECH PHARMACAL CO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 26 2013
    Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation Dec 26 2013

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide